Zhejiang Jolly PharmaceuticalLTD Yönetim

Yönetim kriter kontrolleri 4/4

We currently do not have sufficient information about the CEO.

Anahtar bilgiler

Tao Wang

İcra Kurulu Başkanı

CN¥1.1m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	6.8yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	5.3yrs
Yönetim Kurulu ortalama görev süresi	4.3yrs

Son yönetim güncellemeleri

Recent updates

CEO

Tao Wang (56 yo)

6.8yrs

Görev süresi

CN¥1,092,500

Tazminat

Mr. Tao Wang serves as General Manager at Zhejiang Jolly Pharmaceutical Co., Ltd. since January 16, 2018 and has been its Non-Independent Director since May 10, 2024 and also served as its Senior Manager a...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Tao Wang	GM & Non-Independent Director	6.8yrs	CN¥1.09m	Veri yok
Yuehong Shen	Deputy GM & Non-Independent Director	3.8yrs	CN¥743.10k	Veri yok
Guofu Feng	Executive Deputy GM	2.6yrs	CN¥807.50k	0.095% CN¥ 10.4m
Jian Chen	Deputy General Manager	16.8yrs	CN¥606.70k	0.15% CN¥ 16.5m
Xiao Guo Peng	Deputy General Manager	6.8yrs	CN¥711.50k	Veri yok
Xin Tan	Deputy General Manager	1.8yrs	CN¥721.30k	0.0028% CN¥ 302.5k

5.3yrs

Ortalama Görev Süresi

51.5yo

Ortalama Yaş

Deneyimli Yönetim: 300181's management team is seasoned and experienced (5.3 years average tenure).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Tao Wang	GM & Non-Independent Director	less than a year	CN¥1.09m	Veri yok
Yuehong Shen	Deputy GM & Non-Independent Director	3.8yrs	CN¥743.10k	Veri yok
Guofu Feng	Executive Deputy GM	7.8yrs	CN¥807.50k	0.095% CN¥ 10.4m
Youqiang Yu	Chairman	21.3yrs	CN¥1.03m	18.92% CN¥ 2.1b
Huifen Zhang	Non-Independent Director	3.8yrs	CN¥20.00k	Veri yok
Xuegen Zheng	Non-Independent Director	16.8yrs	CN¥20.00k	0.11% CN¥ 11.6m
Jian Jun Wang	Non-Independent Director	7.8yrs	CN¥20.00k	Veri yok
Bin Pan	Independent Director	4.7yrs	CN¥60.00k	Veri yok
Ping Wang	Independent Director	3.8yrs	CN¥60.00k	Veri yok
Jian Zhu	Independent Director	3.8yrs	CN¥60.00k	Veri yok
Chenghua Zhou	Chairman of the Supervisory Board	6.8yrs	Veri yok	Veri yok
Jie Yao	Independent Director	less than a year	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 300181's board of directors are considered experienced (4.3 years average tenure).

Zhejiang Jolly PharmaceuticalLTD Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Zhejiang Jolly Pharmaceutical Co.,LTD, Annual General Meeting, May 10, 2024

Insufficient new directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Zhejiang Jolly Pharmaceutical Co.,LTD Approves Management Appointments

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.13 in 3Q 2023)

Zhejiang Jolly Pharmaceutical Co.,LTD to Report Q3, 2024 Results on Oct 28, 2024

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: CN¥0.22 (vs CN¥0.14 in 2Q 2023)

Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) announces an Equity Buyback for CNY 300 million worth of its shares.

Now 21% undervalued after recent price drop

Zhejiang Jolly Pharmaceutical Co.,LTD to Report First Half, 2024 Results on Jul 30, 2024

New minor risk - Share price stability

Dividend increased to CN¥0.45

First quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.14 in 1Q 2023)

Zhejiang Jolly Pharmaceutical Co.,LTD, Annual General Meeting, May 10, 2024

Zhejiang Jolly Pharmaceutical Co.,LTD to Report Q1, 2024 Results on Apr 19, 2024

Investor sentiment improves as stock rises 18%

Now 22% overvalued after recent price rise

Investor sentiment deteriorates as stock falls 16%

Insufficient new directors

Zhejiang Jolly Pharmaceutical Co.,LTD to Report Fiscal Year 2023 Results on Apr 19, 2024

Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.11 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.11 in 2Q 2022)

Zhejiang Jolly Pharmaceutical Co.,LTD to Report First Half, 2023 Results on Aug 09, 2023

Zhejiang Jolly Pharmaceutical Co.,LTD Announces Cash Dividend on A Shares for the Year 2022, Payable on 30 May 2023

Zhejiang Jolly Pharmaceutical Co.,LTD Approves Cash Dividend for 2022

Investor sentiment deteriorates as stock falls 16%

Full year 2022 earnings released: EPS: CN¥2.25 (vs CN¥0.29 in FY 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.074 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.07 in 2Q 2021)

Investor sentiment improved over the past week

Zhejiang Jolly Pharmaceutical Co.,LTD Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2021, Payable on 31 May 2022

Zhejiang Jolly Pharmaceutical Co.,Ltd Approves Cash Dividend for 2021

High number of new and inexperienced directors

Zhejiang Jolly Pharmaceutical Co.,LTD Proposes Cash Dividend for 2021

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment deteriorated over the past week

Zhejiang Jolly Pharmaceutical Co.,LTD announced that it expects to receive CNY 910 million in funding

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.074 (vs CN¥0.052 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.07 (vs CN¥0.033 in 2Q 2020)

Investor sentiment improved over the past week

Zhejiang Jolly Pharmaceutical Co.,Ltd Announces Final Cash Dividend for 2020, Payable on 31 May 2021

Zhejiang Jolly Pharmaceutical Co.,Ltd Approves Dividend for the Year 2020

First quarter 2021 earnings released: EPS CN¥0.072 (vs CN¥0.018 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.15 (vs CN¥0.042 in FY 2019)

New 90-day high: CN¥6.86

Full year 2020 earnings released: EPS CN¥0.14 (vs CN¥0.042 in FY 2019)

Zhejiang Jolly Pharmaceutical Co.,LTD to Report Fiscal Year 2020 Results on Apr 13, 2021

Zhejiang Jolly Pharmaceutical Co.,LTD Approves Management Appointments

New 90-day low: CN¥5.90

New 90-day low: CN¥6.22

New 90-day low: CN¥6.59

Third quarter earnings released

New 90-day high - CN¥8.10

Zhejiang Jolly Pharmaceutical Co.,LTD to Report First Half, 2020 Results on Aug 27, 2020

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş